PE20090895A1 - Derivados de triazol como inhibidores de la jak quinasa - Google Patents

Derivados de triazol como inhibidores de la jak quinasa

Info

Publication number
PE20090895A1
PE20090895A1 PE2008001287A PE2008001287A PE20090895A1 PE 20090895 A1 PE20090895 A1 PE 20090895A1 PE 2008001287 A PE2008001287 A PE 2008001287A PE 2008001287 A PE2008001287 A PE 2008001287A PE 20090895 A1 PE20090895 A1 PE 20090895A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrazole
alkenyl
methyl
jak
Prior art date
Application number
PE2008001287A
Other languages
English (en)
Inventor
Lynsie Almeida
Brian Aquila
Claudio Edmundo Chuaqui
Huiping Guan
Shan Huang
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Jie Shi
Mei Su
Quibin Su
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090895A1 publication Critical patent/PE20090895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DERIVADO DE TRIAZOL DE FORMULA (I): DONDE EL ANILLO A ES HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R2; EL ANILLO B ES SELECCIONADO DE CARBOCICLO Y HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R4; X ES -O-, -NH- Y -S-; R1 ES HALO, -CN, ALQUILO(C1-C6), ENTRE OTROS; R2 ES -CN, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6); ALQUINILO(C2-C6), ENTRE OTROS; R4 ES ALQUILO(C1-C6), ALQUENILO (C2-C6), CARBOCILILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-N2-(1-(5-FLUOROPIRIDIN-2-IL)ETIL)-N4-(5-METIL-1H-PIRAZOL-3-IL)-6-(4-METILPIPERAZIN-1-IL)-1,3,5-TRIAZINA-2,4-DIAMINA, (S)-N2-(1-(5-FLUOROPIRIMIDIN-2-IL)ETIL)N4-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZINA-2,4-DIAMINA, 4-(1-(5-FLUOROPIRIDIN-2-IL)ETOXI)-N-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZIN-2-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO TIENE ACTIVIDAD INHIBITORIA DE JAK QUINASA Y ES UTIL EN EL TRATAMIENTO DE TRASTORNOS MIELOPROLIFERATIVOS Y EL CANCER
PE2008001287A 2007-07-31 2008-07-31 Derivados de triazol como inhibidores de la jak quinasa PE20090895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95315807P 2007-07-31 2007-07-31

Publications (1)

Publication Number Publication Date
PE20090895A1 true PE20090895A1 (es) 2009-08-08

Family

ID=40304964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001287A PE20090895A1 (es) 2007-07-31 2008-07-31 Derivados de triazol como inhibidores de la jak quinasa

Country Status (6)

Country Link
AR (1) AR069899A1 (es)
CL (1) CL2008002243A1 (es)
PE (1) PE20090895A1 (es)
TW (1) TW200906818A (es)
UY (1) UY31254A1 (es)
WO (1) WO2009016410A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
WO2010144338A1 (en) * 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
EP2440053A4 (en) * 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
BR112017014980B1 (pt) 2015-01-16 2021-11-16 Bayer Cropscience Aktiengesellschaft Método para preparação de hidrocloreto de 4-cianopiperidina
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US20210246122A1 (en) * 2018-06-22 2021-08-12 Aduro Biotech, Inc. Triazine Compounds and Uses Thereof
CN109020951B (zh) * 2018-08-24 2020-06-02 大连理工大学 含三取代三聚氯氰的萘酰亚胺类衍生物及其合成方法和应用
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022605A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1485381B8 (en) * 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine as inhibitors of protein kinases
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
JP2009513615A (ja) * 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体

Also Published As

Publication number Publication date
WO2009016410A3 (en) 2009-07-02
AR069899A1 (es) 2010-03-03
WO2009016410A2 (en) 2009-02-05
UY31254A1 (es) 2009-04-30
CL2008002243A1 (es) 2009-08-21
TW200906818A (en) 2009-02-16

Similar Documents

Publication Publication Date Title
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20141681A1 (es) Inhibidores de btk
PE20140934A1 (es) Derivados de pirazol
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20131377A1 (es) Triazina-oxadiazoles
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20100087A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20140609A1 (es) Diazacarbazoles y metodos de uso
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.

Legal Events

Date Code Title Description
FD Application declared void or lapsed